Comparative Pharmacology
Head-to-head clinical analysis: HYDRO SERP 50 versus METATENSIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO SERP 50 versus METATENSIN 2.
HYDRO-SERP "50" vs METATENSIN #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
Hydrochlorothiazide 50 mg orally once daily.
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
None Documented
None Documented
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination